Laura Fernandez
Majadahonda, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant.
Journal: Microorganisms
Published: September 22, 2021
Cellular Markers of Active Disease and Cure in Different Forms of Leishmania infantum-Induced Disease.
Journal: Frontiers in cellular and infection microbiology
Published: June 18, 2018
Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters.
Journal: Frontiers in immunology
Published: November 20, 2017
F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis.
Journal: Frontiers in immunology
Published: April 07, 2017
Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.
Journal: PLoS neglected tropical diseases
Published: March 16, 2017
Lymphoproliferative response after stimulation with soluble leishmania antigen (SLA) as a predictor of visceral leishmaniasis (VL) relapse in HIV+ patients.
Journal: Acta tropica
Published: May 18, 2016
Cytokine Release Assays as Tests for Exposure to Leishmania, and for Confirming Cure from Leishmaniasis, in Solid Organ Transplant Recipients.
Journal: PLoS neglected tropical diseases
Published: June 16, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026